Background
Methods
Patient inclusion criteria and data collection
Inclusion criteria | Exclusion criteria |
---|---|
Aged 18 years or above. | Known or suspected infection at the time of consideration for the study. |
Patients with confirmed aneurysmal SAH who have had an EVD inserted as part of their clinical care, that is expected to remain in situ for more than 48 hours. | Known allergy to Escherichia coli or any of the constituents of the study medication as established from the patient themselves, reliable representative, or clinical records. |
IL-1Ra or placebo can be administered within 72 hours from ictus. | Previous or existing treatment with IL-1Ra. |
Patients are likely to remain resident within the study centre for the next 7 days. | Previous or current treatment with medication suspected of interacting with IL-1Ra, such as TNF-α inhibitors. |
Normal renal function (serum creatinine <177 μmol L-1). | Known to have participated in a clinical trial of an investigational agent or device in the previous 30 days or for the period determined by the protocol of the study the patient has taken part in. |
Willing and able to give informed consent or consent available from a patient’s personal representative (usually the next of kin) for study inclusion including agreement in principle to receive study intervention and undergo all study assessments. | Known pregnancy or breast-feeding. |
Clinically significant concurrent medical condition which, at the CI’s (or designee’s) discretion, could affect the safety, tolerability, or efficacy in this study or would interfere with participation, administration of study treatment, or assessment of outcomes. For example, pre-existing malignancy. | |
Previous inclusion in the current study. | |
Inability or unwillingness of patient or patient’s personal representative to give written informed consent. |
Cytokine assays
Analyte | Plasma | CSF | ||
---|---|---|---|---|
Sensitivity (pg/mL) | Inter-assay CV range (QC concentration range) | Sensitivity (pg/mL) | Inter-assay CV range (QC concentration range) | |
IL-1Ra | 16 | 8.2 to 3.2 (360 to 10,009 pg/mL) | Same assay as for plasma | |
IL-1α | 6.1 | 9.0 to 4.2 (25 to 366 pg/mL) | 4.75 | 6.6 to 9.2 (20 to 800 pg/mL) |
IL-1β | 1.3 | 10.3 to 6.3 (17.5 to 146 pg/mL) | 0.48 | 30.3 to 10.9 (1.3 to 10.9 pg/mL) |
IL-6 | 1.7 | 5.9 to 2 (41 to 322 pg/mL) | 17 | 7.1 to 2.6 (213 to 1,229 pg/mL) |
IL-8 | 4.7 | 7.9 to 16 (109 to 975 pg/mL) | 17 | 8.9 to 15.8 (185 to 9,152 pg/mL) |
IL-10 | 1.3 | 10.3 to 6.26 (7.5 to 146 pg/mL) | 0.82 | 10.6 to 5.5 (5.16 to 232 pg/mL) |
MCP-1 | 45 | 19.5 to 11.3 (207 to 1,759 pg/mL) | 147 | (19 to 6.5 (9,303 to 11,275 pg/mL) |
TNF-α | 0.35 | 6.7 to 7.0 (16.8 to 159 pg/mL) | 2.5 | 25 to 15.8 (4.3 to 28.1 pg/mL) |
CRP | 350 | 14.8 to 1 (9.2 to 97 mg/L) | ND |
Statistical analysis
Results
Recruitment and baseline characteristics
All patients (n = 13a) | Placebo (n = 7) | IL-1Ra (n = 6) | |
---|---|---|---|
Mean age (range) (years) | 54 (40 to 69) | 50 (42 to 61) | 58 (40 to 69) |
Male/female | 3/10 | 1/6 | 2/4 |
WFNS grade | |||
1 | 1 | 1 | 0 |
2 | 5 | 4 | 1 |
3 | 0 | 0 | 0 |
4 | 3 | 1 | 2 |
5 | 4 | 1 | 3 |
Fisher grade | |||
3 | 3 | 2 | 1 |
4 | 10 | 5 | 5 |
Aneurysm location | |||
Anterior circulation | 9 | 5 | 4 |
Posterior circulation | 4 | 2 | 2 |
Placebo | IL-1Ra |
---|---|
Fluctuating GCS | Raised ICP; hypotensiona
|
Desaturation; cardiac arrhythmia; meningitis | Chest sepsis; focal seizures cardiac arrhythmia; increased urine output; increased CRPa
|
IV line infection; chest infection; focal seizure | Ventilator-associated pneumonia |
Leaking wounda
| |
Acute agitationa; pyrexia of unknown origina
|
Changes in plasma and CSF IL-6 following IL-1Ra administration
Changes in other measures of inflammation
Placebo | IL-1Ra | ||||||
---|---|---|---|---|---|---|---|
Mediator | Location | Raw | Adjusted | Raw | Adjusted | Difference |
Pvalue |
IL-6 | CSF | 107.3 | 0.2 | 111.0 | −12.6 | 12.8 (−2.1 to 27.7) | 0.08 |
Plasma | 37.7 | −3.7 | 49.7 | −22.3 | 18.6 (−0.6 to 37.7) | 0.06 | |
IL-8 | CSF | 114.8 | 4.8 | 104.7 | −2.3 | 7.1 (−5.4 to 19.5) | 0.23 |
Plasma | 37.8 | 6.4 | 39.8 | −0.3 | 6.7 (−4.9 to 18.3) | 0.23 | |
IL-10 | CSF | 14.6 | −6.3 | 25.0 | −8.1 | 1.8 (−8.6 to 12.2) | 0.70 |
Plasma | 6.7 | 0.5 | 9.1 | −17.1 | 17.6 (4.3 to 30.9) | 0.01 | |
MCP-1 | CSF | 139.8 | 1.5 | 145.4 | −4.0 | 5.5 (−3.9 to 15.0) | 0.22 |
Plasma | 68.7 | −4.3 | 79.2 | −4.0 | −0.3 (−14.0 to 13.3) | 0.96 | |
CRP | Plasma | 65.2 | −1.6 | 84.5 | −0.5 | −1.1 (−10.3 to 8.1) | 0.79 |
Clinical outcome
Treatment group | GOS | |
---|---|---|
Good (GOS 4 to 5) | Poor (GOS 1 to 3) | |
Placebo | 5 | 1 |
IL-1Ra | 5 | 1 |
Total | 10 | 2 |